MDG1.F Medigene AG (XETRA) +35% intraday on 17 Mar 2026: check liquidation value

MDG1.F stock jumped 35.17% intraday to €0.0392 on XETRA on 17 Mar 2026, driven by heavy volume and renewed attention to the company’s liquidation process. Traders executed 29,701 shares versus an average of 12,630, sending the penny stock well above its open of €0.0332. The move highlights speculative flows in a low‑cap biotech in liquidation and forces a reassessment of potential recovery value per share versus current market pricing.

Intraday price action and liquidity

Medigene AG (MDG1.F) topped the XETRA intraday list after a one‑day rise of 35.17% to €0.0392 with a day high of €0.0392 and a day low of €0.0332. Volume surged to 29,701 shares, a relative volume of 2.35, while average volume is 12,630, indicating outsized interest for this micro‑cap.

The stock opened at €0.0332 versus a previous close of €0.0290, and market cap sits near €607,189. Short windows and low float create rapid swings; intraday traders should expect volatile executions and wide spreads on XETRA.

Catalysts behind the move: liquidation and calendar events

Medigene AG is reported to be in the process of liquidation of remaining assets, a fact that drives speculative trading and occasional re‑rating of share value. The company lists an upcoming earnings announcement on 26 Mar 2026, which may provide clarity on remaining cash, liabilities, and next steps in the liquidation.

With 14,737,594 shares outstanding and a tiny market cap, any news about asset realisation, creditor settlements or tender offers can move the stock sharply. Traders reacted today to rumours and positioning ahead of the formal update.

Fundamentals and valuation snapshot for MDG1.F stock

Fundamentally Medigene shows a deep‑value profile on paper but with operating losses: EPS -1.21, PE -0.03, cash per share €1.29, and book value per share €1.63. Price to book is extremely low at about 0.03 (price €0.0392 vs book €1.63), reflecting market pricing of liquidation uncertainty.

Revenue per share is €0.47 and the company reports a current ratio near 2.53, signalling short‑term solvency. However, operating cashflow per share is -€1.17, and free cash flow per share is -€1.22, underlining historic operating losses and execution risk.

Technicals and Meyka AI grading

Technically MDG1.F stock sits below its 50‑day average ~€0.04 and 200‑day average ~€0.06, but today’s spike pushed price toward the 50‑day band. Momentum indicators show RSI 43.53, MFI 10.61 (oversold prior to the move), and ADX 16.05 (no clear trend). Bollinger bands are tight: upper €0.04, middle €0.04, lower €0.03.

Meyka AI rates MDG1.F with a score out of 100: 62.57 | Grade B | Suggestion: HOLD. This grade factors S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. These grades are informational only and not financial advice.

Price targets, Meyka AI forecast and implied upside

Meyka AI’s forecast model projects a conservative base‑case target of €0.30 for MDG1.F stock, reflecting possible partial recovery from liquidation proceedings. Compared with the current price of €0.0392, that implies an upside of 665.31%. A book‑value recovery scenario at €1.63 implies an upside of 4,056.93%, but that outcome is far more uncertain.

Forecasts are model‑based projections and not guarantees. Given the firm’s liquidation status, outcomes range from near‑zero recovery to sizable payouts depending on asset sales, creditor settlement and legal costs.

Risks, sector context and trading strategy

Medigene operates in the Healthcare / Biotechnology sector where the German sector YTD performance is mixed; Healthcare 1‑day performance is +0.90% while YTD stands near -2.12%. Biotech liquidation stories are binary: either investors recover meaningful cash or legal and creditor claims erase equity value.

For traders we suggest tight position sizing, clear stop losses and awareness of low liquidity. Active traders may capture spikes, but holders should monitor the 26 Mar 2026 announcement and any official liquidation notices closely.

Final Thoughts

MDG1.F stock’s 35.17% intraday surge to €0.0392 on XETRA reflects speculative buying around Medigene AG’s liquidation story and an elevated trading volume of 29,701. Meyka AI’s forecast model projects a conservative base‑case target of €0.30, implying 665.31% upside versus the current price, while a full book‑value recovery near €1.63 would imply a far larger return. Meyka AI’s proprietary grade for MDG1.F is 62.57 (B, HOLD), which blends sector comparisons, financial growth, key metrics and analyst signals.

These figures frame the opportunity and the risk: the upside can be large if assets realise value above market price, but outcomes are binary and liquidity is low. Traders should treat MDG1.F as a high‑volatility, event‑driven micro‑cap and size positions accordingly. For official company details and filings consult the Medigene investor site and market data providers before acting. Forecasts are model‑based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.